Clinical and metabolic features of diabetic encephalopathy

Abstract

BACKGROUND: Actual mindset, concerning the pathogenesis of type 2 diabetes mellitus and its complications, is described in the glucocentric, lipocentric and lipokine theories. At the same time, it is known, that acute cerebrovascular disorder in type 2 diabetes mellitus can also develop with normoglycemia. The mechanism of association between obesity and type 2 diabetes mellitus in metabolic syndrome has not yet been studied, and 40% of diabetic patients are not obese. In the physiological state hyperglycemia is prevented by pancreatic regulatory oligopeptides rather than insulin, and protein glycation occurs before the development of diabetes symptoms. That facts indicate the need to continue investigation of the pathogenesis in general and diabetic encephalopathy in particular from the standpoint of metabology in order to substantiate the peptidergic theory of the diabetes mellitus and dyscirculatory encephalopathy pathogenesis.

AIM: To consider little-known clinical, morphological and metabolic manifestations of diabetic encephalopathy from the standpoint of improving the disease diagnosis.

MATHERIALS AND METHODS: Among 162 elderly and senile patients in the pre-stroke and stroke stages of diabetic encephalopathy, modern methods of radiological, laboratory, histological, psychometric and clinical analysis have been used: the relationship between low total cholesterol and disease progression has been determined according to Schulte and MMSE psychometric tests with the same hyperglycemia in different age groups sick; cases of amyloid angioencephalopathy on magnetic resonance imaging in the ultrasensitive weighted imaging mode and amyloidosis have been identified.

Staining post-mortem ultrathin tissue biopsy sections with Congo red allowed to find amyloid deposition in 12% of autopsy cases in the absence of diagnosing amyloidosis during life; preparations, in which Congo red staining was positive for the presence of amyloid, were taken for inspection in polarizing light and typing of amyloid. Staining of histological preparations with hematoxylin-eosin and Van Gieson revealed a morphological characteristic of diabetic encephalopathy different from that of atherogenic and hypertensive dyscirculatory encephalopathy; using immunological studies, a statistically significant increased content of induced interleukin-1β production, a trigger for the serum amyloid analogue in the liver synthesis, was determined, and an experimental method for beta-amyloid peptide adhesion by monocytes and the density of amyloid expression on the surface of monocytes in patients with diabetic encephalopathy at senile age at 2–3 times higher than the density of the peptide in the elderly and in the patients with dyscirculatory encephalopathy of the same old age.

RESULTS: It has been established that a fairly frequent and early manifestation of metabolic disorders in diabetic encephalopathy is a violation of protein metabolism with its final conformation into toxic amyloid tissue components. These observations indicate the multifactorial nature of diabetic encephalopathy. Literature data on the parametabolism of the serotonin mediator and tryptophan in the pathogenesis of diabetic encephalopathy are presented.

CONCLUSIONS: Modern immunological, morphological, and histochemical capabilities make it possible to diagnose the conformation of the protein matrix and develop a protein-centric hypothesis of diabetic encephalopathy.

Keywords

diabetes mellitus type 2 / diabetic encephalopathy / cognitive impairment / amyloidosis / Magnetic Resonance Imaging in susceptibility weighted imaging mode / Congo-red / interleukin-1β / diabetic amyloid angioencephalopathy

References

[1] Merkulov GA. Kurs patologo-gistologicheskoi tekhniki. Moscow: Medicina; 1969. (In Russ.)

[2] Меркулов Г.А. Курс патолого-гистологической техники. М.: Медицина, 1969.

[3] Roshchin DO, Sabgaida TP, Sekrieru EM. Printsipy kodirovaniya sostoyanii u lits, stradayushchikh sakharnym diabetom: metodicheskie rekomendatsii. Moscow; 2013. (In Russ.)

[4] Рощин Д.О., Сабгайда Т.П., Секриеру Е.М. Принципы кодирования состояний у лиц, страдающих сахарным диабетом: методические рекомендации. М., 2013.

[5] Batysheva TT, Ryzhak AA, Novikova LA. Osobennosti ONMK u bol’nykh sakharnym diabetom. Lechashchii vrach. 2004;(1):30–35. (In Russ.)

[6] Батышева Т.Т., Рыжак А.А., Новикова Л.А. Особенности ОНМК у больных сахарным диабетом // Лечащий врач. 2004. № 1. С. 30–35.

[7] Yanishevskii SN. Porazhenie golovnogo mozga pri sakharnom diabete 2-go tipa [dissertation]. Saint Petersburg; 2014. (In Russ.)

[8] Янишевский С.Н. Поражение головного мозга при сахарном диабете 2-го типа: автореф. дис. … д-ра мед. наук. СПб.: ВМА, 2014.

[9] Ketlinskii SA, Alekseeva TG, Perumov ND, Simbirtsev AS. The content of interleukin-1 beta in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis. Ter Arkh. 1993;65(12):51–54. (In Russ.)

[10] Кетлинский С.А., Алексеева Т.Г., Перумов Н.Д., Симбирцев А.С. Исследование содержания интерлейкина-1β в сыворотке крови больных системной красной волчанкой и ревматоидным артритом // Терапевтический архив. 1993. Т. 65, № 12. С. 51–54.

[11] Zhuravleva LV, Sokolnikova NV. The role of interleukin-1β in the formation of diabetic cardiomyopathy in patients with overweight. Klіnіchnіdoslіdzhennja. Dіabet і serce. 2015;2(188):41–44. (In Russ.)

[12] Журавлева Л.В., Сокольникова Н.В. Роль интерлейкина-1β в формировании диабетической кардиомиопатии у больных с повышенной массой тела // Клінічнідослідження. Діабет і серце. 2015. № 2(188). С. 41–44.

[13] Golovkin VI, Ovdienko OA, Tikhonova ML, et al. Efficient treatment to beta-amyloid vasculitis. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2017;9(2):114–116. (In Russ.)

[14] Головкин В.И., Овдиенко О.А., Тихонова М.Л. и др. Случай эффективного лечения бета-амилоидного церебрального васкулита // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2017. Т. 9, № 2. С. 114–116.

[15] Golovkin VI, Gulak DA, Davydova NI. Interleikin-1β v doinsul’tnoi stadii diabeticheskoi entsefalopatii. Proceedings of the conference “Botkinskie chteniya”, May 29–31, 2018; Saint Petersburg. Saint Petersburg; 2018. P. 92–93. (In Russ.)

[16] Головкин В.И., Гулак Д.А., Давыдова Н.И. Интерлейкин-1β в доинсультной стадии диабетической энцефалопатии // Материалы конференции «Боткинские чтения», Санкт Петербург, 29–31 мая 2018 г. СПб., 2018. С. 92–93.

[17] Golovkin VI, Gulak DA, Magonov EP. Differentsial’naya MRT-diagnostika diabeticheskoi i distsirkulyatornoi entsefalopatii. Proceedings of the conference “XX Davidenkovskie chteniya”, Sept. 27–28, 2018; Saint Petersburg. Saint Petersburg; 2018. P. 94–95. (In Russ.)

[18] Головкин В.И., Гулак Д.А., Магонов Е.П. Дифференциальная МРТ-диагностика диабетической и дисциркуляторной энцефалопатии // Материалы конференции «ХХ Давиденковские чтения», Санкт-Петербург, 27–28 сентября 2018 г. СПб., 2018. С. 94–95.

[19] Shishkin AN, Stroyev YuI, Churilov LP, et al. Classic and modern concepts of the metabolic syndrome. Part III. Prevention and treatment. Vestnik of Saint Petersburg University. Medicine. 2009;(3):24–37. (In Russ.)

[20] Шишкин А.Н., Строев Ю.И., Чурилов Л.П. и др. Классические и современные представления о метаболическом синдроме. Часть 3. Лечение и профилактика // Вестник Санкт-Петербургского университета. Медицина. 2009. № 3. С. 24–37.

[21] Mustafina SV. Risk sakharnogo diabeta i metabolicheskii sindrom: populyatsionnoe issledovanie v Sibiri [dissertation]. Novosibirsk; 2016. (In Russ.)

[22] Мустафина С.В. Риск сахарного диабета и метаболический синдром: популяционное исследование в Сибири: автореф. дисс. … д-ра мед. наук. Новосибирск, 2016.

[23] Mikroskopicheskaya tekhnika: Rukovodstvo dlya vrachei i laborantov. Ed. by D.A. Sarkisov, Yu.L. Perov. Moscow: Meditsina, 1996. P. 36–50. (In Russ.)

[24] Микроскопическая техника: Руководство для врачей и лаборантов / под ред. Д.А. Саркисова, Ю.Л. Перова. М.: Медицина, 1996. С. 36–50.

[25] Serov VV. Starcheskii amiloidoz: ot tetrady Shvartsa do nastoyashchego vremeni. RMJ. 1997;5(20):46–53. (In Russ.)

[26] Серов В.В. Старческий амилоидоз: от тетрады Шварца до настоящего времени // РМЖ. 1997. Т. 5, № 20. С. 46–53.

[27] Tabeeva GR, Azimova YuE. Tserebrovaskulyarnye rasstroistva v pozhilom vozraste. Prakticheskoe rukovodstvo dlya vrachei. Practical medicine. 2010:1–56. (In Russ.)

[28] Табеева Г.Р., Азимова Ю.Э. Цереброваскулярные расстройства в пожилом возрасте. Практическое руководство для врачей // Практическая медицина. 2010. С. 1–56.

[29] Syvorotochnyi amiloid A pri vospalenii [Internet]. Available from: https://dommedika.com/phisiology/435.html. Accessed: June 16, 2022.

[30] Сывороточный амилоид А при воспалении [Электронный ресурс]. Режим доступа: https://dommedika.com/phisiology/435.html. Дата обращения: 16.06.2022.

[31] Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580(12):2917–2921. DOI: 10.1016/j.febslet.2006.04.028

[32] Matsuzawa Y. The metabolic syndrome and adipocytokines // FEBS Lett. 2006. Vol. 580, No. 12. P. 2917–2921. DOI: 10.1016/j.febslet.2006.04.028

[33] de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7(1):45–61. DOI: 10.3233/jad-2005-7106

[34] de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease // J. Alzheimers Dis. 2005. Vol. 7, No. 1. P. 45–61. DOI: 10.3233/jad-2005-7106

[35] McNay EC, Recknagel AK. Brain insulin signaling: A key compont of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem. 2011;96(4):517–528. DOI: 10.1016/j.nlm.2011.11.001

[36] McNay E.C., Recknagel A.K. Brain insulin signaling: A key compont of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes // Neurobiol. Learn. Mem. 2011. Vol. 96, No. 4. P. 517–528. DOI: 10.1016/j.nlm.2011.11.001

[37] HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo- controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291. DOI: 10.1093/eurheartj/eht055

[38] HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo- controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment // Eur. Heart J. 2013. Vol. 34, No. 17. P. 1279–1291. DOI: 10.1093/eurheartj/eht055

[39] The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–828. DOI: 10.1056/NEJMoa1006524

[40] The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes // N. Engl. J. Med. 2011. Vol. 364, No. 9. Р. 818–828. DOI: 10.1056/NEJMoa1006524

[41] Hohsfield LA, Humpel C. Intravenous Infusion of monocytes isolated from 2-week-old mice enhances clearance of beta-amyloid plaques in an alzheimer mouse model. PLoS One. 2015;10(4):e0121930. DOI: 10.1371/journal.pone.0121930

[42] Hohsfield L.A., Humpel C. Intravenous infusion of monocytes isolated from 2-week-old mice enhances clearance of beta-amyloid plaques in an Alzheimer mouse model // PLoS One. 2015. Vol. 10, No. 4. P. e0121930. DOI: 10.1371/journal.pone.0121930

[43] Eisele YS, Monteiro C, Fearns C, Encalada SE, et al. Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov. 2015;14(11):759–780. DOI: 10.1371/10.1038/nrd4593

[44] Eisele Y.S., Monteiro C., Fearns C., Encalada S.E. et al. Targeting protein aggregation for the treatment of degenerative diseases // Nat. Rev. Drug. Discov. 2015. Vol. 14, No. 11. P. 759–780. DOI: 10.1038/nrd4593

[45] Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alzheimers Dis. 2012;2012:489456. DOI: 10.1155/2012/489456

[46] Wilkinson K., El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease // Int. J. Alzheimers Dis. 2012. Vol. 2012. P. 489456. DOI: 10.1155/2012/489456

RIGHTS & PERMISSIONS

Golovkin V.I., Privalova M.A., Garan T.A., Gulak D.A.